Dr. Mohammad Ali Abbass, MD

Dr. Abbass practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Abbass' NPI, 1730508052, was assigned on April 15, 2014. Dr. Abbass graduated from Damascus University Faculty of Medicine in 2009. Dr. Abbass holds Illinois license 036153116.

Dr. Abbass' primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Abbass' primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center (MSK), Department of Surgery. Dmand AI also links Dr. Abbass to 5 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abbass practices. Vendor and product names are available with a free account.

Colon and rectal surgery is Dr. Abbass' primary specialty in the NPI Registry, under taxonomy code 208C00000X. Dr. Abbass is board certified in colon & rectal surgery by the American Board of Colon and Rectal Surgery. Dmand AI has Dr. Abbass' licenses on file in 4 states: Illinois, California, New York and Ohio.

Dmand AI lists colonoscopy, colon removal, gastrointestinal obstruction and hemorrhoids among the conditions Dr. Abbass treats.

CMS data shows 65 Medicare services from Dr. Abbass across 2 procedure codes in 2024, for 86 Medicare patients. Medicare paid $6,024 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 86 Medicare patients who saw Dr. Abbass in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abbass' median patient age at 67, with 55% women.

In 2024, Dr. Abbass wrote 68 Medicare Part D claims for 26 patients. 97% of them were for generic drugs. CMS names the drug for 25 of them, across 2 drugs with 11 or more claims each, at $112 in total drug cost. In 2023, CMS named 78 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Abbass for performance year 2024, reported through an alternative payment model (APM). Dr. Abbass accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Abbass as offering telehealth. CMS counts 84 procedures of colonoscopy by Dr. Abbass, more than 76% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 12 papers to Dr. Abbass, published from 2015 to 2025. 2023 was the busiest year, with 2. The most frequent topics are Colorectal Neoplasms, Hereditary Nonpolyposis, Adenomatous Polyposis Coli and Colonic Neoplasms. Dr. Abbass has published most often in Dis Colon Rectum. Dr. Abbass' most frequent co-authors are James M. Church, MD, Maher A. Abbas, MD and Sherif R. Aboseif, MD.

CMS Open Payments shows 23 general payments to Dr. Abbass from 9 drug and device companies from 2019 to 2025. Education make up the largest share, 59% of the total. Intuitive Surgical, Inc. paid the most, $4,634.

Dr. Abbass graduated from Damascus University Faculty of Medicine in 2009.

Dr. Abbass is in network with 14 carriers, including Aetna, Elevance and HCSC. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.